Tier 2 — strong

Effect of high dose N-acetyl cysteine supplementation on markers of oxidative stress and insulin resistance in non-diabetic patients with metabolic dysfunction associated steatotic liver disease: a randomized controlled trial

Asmaa Mohammad Ramadan, Lamia M El-Wakeel, AbdulMoneim Adel, Mohamed Abdel-Wahab, Sarah Farid Fahmy
BMC Gastroenterol 2026 26:500

Bibliography

PubMed
PMID 42587287
PubMed Central
PMC13465645
DOI
10.1186/s12876-026-05157-x
Funding
The authors reported no financial support for the research, authorship, or publication.
Competing interests
The authors declared no competing interests.

Study snapshot

DesignProspective randomized open-label controlled trial
ModelHuman
Sample60 non-diabetic adults with MASLD: 30 NAC plus lifestyle and 30 lifestyle alone
InterventionOral NAC 2,400 mg/day plus lifestyle intervention versus lifestyle intervention alone
Duration12 weeks
EndpointsMalondialdehyde; Insulin resistance; Lipids; FibroScan steatosis; Fibrosis measures; Quality of life

What the study showed, in plain terms

2026 randomized trial testing high-dose oral NAC as an adjunct to lifestyle intervention in non-diabetic MASLD.

Key findings

NAC did not significantly improve the primary oxidative-stress endpoint, insulin resistance, FibroScan steatosis or fibrosis compared with lifestyle control.

What this study can and cannot tell us

Open-label, 60-person trial over 12 weeks; lifestyle co-intervention and short duration limit conclusions about long-term liver outcomes.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology